

ASX: CVB

8 July 2026

## CurveBeam AI secures commitments for \$5.0m Placement and announces \$1m Share Purchase Plan

- **Binding commitments received for a A\$5 million institutional and related party placement at A\$0.02 per new share (“Placement”), subject to shareholder approval**
- **A proposed Share Purchase Plan to be made available to eligible shareholders in Australia and New Zealand targeting to raise up to a further A\$1 million at A\$0.018 per new share**
- **Advance by director Arun Singh of A\$2.05m to the Company to continue normal course of trading**
- **Net proceeds to fund Sales & Marketing, R&D, Supply Chain, with a particular focus on the China market launch, along with offer costs and working capital**

### Overview

**Melbourne, Australia & Hatfield, Pennsylvania:** CurveBeam AI Limited (ASX: CVB) (“**CVB**”, “**CurveBeam AI**” or the “**Company**”), a developer of point-of-care specialised medical imaging (CT) equipment and AI-enabled SaaS-based clinical assessment solutions, is pleased to announce that it has executed subscription agreements with institutional and related party investors, including two directors, Greg Brown and Arun Singh, for a non-underwritten placement to raise \$5.0m, subject to shareholder approval (“**the Placement**”).

The Placement comprises the issue of approximately 250,000,000 new fully paid ordinary shares (“**New Shares**”) at a price of A\$0.02 per share (“**Offer Price**”). New Shares issued under the Placement will rank equally with existing CVB shares as at their date of issue.

The Offer Price represents a premium of 11.1% to the last closing price of A\$0.018 per share on 3 July 2026 and an 8.8% discount to the 5-day volume weighted average price (“**VWAP**”) for the week ended 3 July 2026 (A\$0.02194).

The Placement has been sourced as summarised below:

Sources	Amount (A\$)
CEO & Director – Greg Brown	A\$ 300,000
President & Director – Arun & Susmita Singh	A\$ 2,050,000
Other Investors	A\$ 2,650,000

The placements from Director related parties require shareholder approval under ASX Listing Rule 10.11. The balance of the Placement will also be conditional on obtaining shareholder approval for the purposes of ASX Listing Rule 7.1 to preserve the Company’s placement capacity under ASX Listing Rules.

### **Loan**

Mr Arun Singh, who is participating in the Placement, has agreed to advance \$2,050,000 to the Company by way of an unsecured loan (“**Loan**”). The Loan is on arm’s length commercial terms with an interest rate of 5% per annum, with interest payable on maturity. The Loan is repayable on the earlier of 1 October 2027 or the day that Mr Singh subscribes for his New Shares under the Placement (set off against his obligation to pay the subscription price for the New Shares to the extent of the principal under the Loan).

### **Use of Funds**

Proceeds from the capital raising are intended to be applied towards the following:

- Sales & marketing expenses including China market launch preparation for the HiRise™;
- Research & development costs including product enhancements for the HiRise™;
- Supply chain costs including preparing for China market launch; and
- General working capital purposes including capital raising fees.

### **Share Purchase Plan**

CVB will also offer eligible shareholders the opportunity to participate in a non-renounceable non-underwritten Share Purchase Plan (“**SPP**”) targeting around A\$1 million and accepting oversubscriptions.

Under the SPP, shareholders with a registered address in Australia or New Zealand on CVB’s register at 7:00pm AEST on 7 July 2026 (the “**Record Date**”) will have the opportunity to apply for up to a maximum of A\$100,000 of new fully paid ordinary shares, free of any brokerage, commission or other transaction costs, irrespective of the size of their holding.

New shares issued under the SPP will be issued at a price of A\$0.018 per share, and will rank equally with existing CVB shares as at their date of issue. The SPP will be subject to the eligibility criteria and other terms and conditions set out in the SPP prospectus to be released to the ASX on or about 29 July 2026.

The SPP is not underwritten and will not be subject to shareholder approval. As the maximum subscription per shareholder exceeds \$30,000, the Company cannot rely on ASIC Instrument 2019/547 and therefore the offer will be made under a prospectus to be lodged with ASIC and released to the ASX in due course.

Of the maximum 111,111,111 shares to be issued under the SPP, 67,678,662 would be issued under the Company’s available placement capacity under Listing Rule 7.1 and 43,432,448 would be issued under the Company’s available placement capacity under Listing Rule 7.1A.

The Company reserves the right (in its absolute discretion) to accept over subscriptions and to scale back applications.

### **Indicative Placement and SPP Timetable**

Event	Date
<b>Placement</b>	
Announcement of Placement results and SPP	8 July 2026
Trading halt lifted and shares resume normal trading	8 July 2026
Despatch Notice of Meeting for General Meeting to approve Placement	22 July 2026
Convene Meeting of Members to consider Placement	21 August 2026

For personal use only

Settlement of New Shares issued under the Placement	26 August 2026
Allotment of New Shares issued under the Placement	27 August 2026
<b>Share Purchase Plan</b>	
Record Date for SPP (7:00pm, Sydney time)	7 July 2026
SPP Offer opens and Prospectus lodged with ASIC and released on ASX and despatched to Shareholders	29 July 2026
SPP Offer closes (5:00pm, Sydney time)	21 August 2026
Announcement of SPP results	25 August 2026
Settlement of New Shares under the SPP	27 August 2026
Allotment of New Shares under the SPP	28 August 2026

Greg Brown, CVB Director and CEO, said: “Over the past months, the Company has undertaken a comprehensive review of funding alternatives with a clear objective of securing capital in the least dilutive manner possible, while bridging the business to our targeted NMPA clearance in H1 FY27, which we believe has the potential to be a significant value and cashflow inflection point. We explored both debt and equity financing. While we progressed debt discussions to a formal term sheet, the decline in the Company’s market capitalisation ultimately limited the availability of that funding pathway. Against a challenging market backdrop for healthcare microcaps, the Board and management elected to lead this capital raising themselves, demonstrating their conviction in the Company’s strategy and long-term outlook. Importantly, this approach has enabled the Company to raise capital without significant option coverage that may lead to further dilution, a common occurrence in other healthcare microcap financings. Given the current share price, the Board also considered it important to include a meaningful Share Purchase Plan, providing existing shareholders with the opportunity to participate alongside directors on improved terms, should they wish to do so.”

**Release approved by the Board of Directors.**

### About CurveBeam AI Limited

CurveBeam AI Limited (ASX: CVB) develops, manufactures and sells specialised medical imaging (“CT”) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company’s flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non-weightbearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

### Investor / media enquiries

Matthew Wright  
 NWR Communications  
 +61 (0) 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For personal use only